

LIST OF FIGURES

Figure 1. 1: Prevalence of schizophrenia compared to other well-known diseases.....	1
Figure 1. 2: RNAi mechanism	3
Figure 2. 1: Functions of NRG1 in central nervous system.....	19
Figure 2. 2: Pathways for RNAi therapeutics	22
Figure 2. 3: Schematic representation of barriers present in brain	32
Figure 2. 4: Pathways for brain targeting by intranasal route.....	34
Figure 2. 5: Factors affecting absorption and permeability of therapeutics across nasal mucosa	36
Figure 2. 6: Formulations for nasal drug delivery	37
Figure 3. 1: Calibration curve of siRNA comparing observed and actual concentration	57
Figure 3. 2: Detection of quantifiable range of siRNA by agarose gel electrophoresis	59
Figure 3. 3: Agarose gel electrophoresis band density at various siRNA concentrations	60
Figure 3. 4: Calibration curve of siRNA gel electrophoresis.....	61
Figure 3. 5: Accuracy and precision of agarose gel electrophoresis assay	62
Figure 4. 1: Synthesis of bPEI-HA copolymer by carbodiimide reaction	67
Figure 4. 2: Synthesis of bPEI-Lf conjugate by periodate oxidation method.....	68
Figure 4. 3: Synthesis of bPEI-Chi copolymer using carbonyldiimidazole as crosslinker	69
Figure 4. 4: Synthesis of biodegradable bPEI using 1,6-hexanediol diacrylate	71
Figure 4. 5: NMR spectra of bPEI (25kDa).....	74
Figure 4. 6: NMR spectra of HA	74
Figure 4. 7: NMR spectra of bPEI-HA copolymer	75
Figure 4. 8: NMR spectra of bPEI-Lf conjugate.....	76
Figure 4. 9: NMR spectra of Chi	76
Figure 4. 10: NMR spectra of bPEI-Chi copolymer	77
Figure 4. 11: NMR spectra of bPEI (0.8kDa).....	78
Figure 4. 12: NMR spectra of biodegradable crosslinked bPEI	78
Figure 4. 13: FT-IR spectra of bPEI (25kDa)	79
Figure 4. 14: FT-IR spectra of HA.....	80

Figure 4. 15: FT-IR spectra of bPEI-HA copolymer	80
Figure 4. 16: FT-IR spectra of Lf.....	81
Figure 4. 17: FT-IR spectra of bPEI-Lf conjugate.....	82
Figure 4. 18: FT-IR spectra of Chi.....	83
Figure 4. 19: FT-IR spectra of bPEI-Chi copolymer	83
Figure 4. 20: FT-IR spectra of PEI (0.8 kDa)	84
Figure 4. 21: FT-IR spectra of biodegradable bPEI.....	84
Figure 4. 22: Molecular weight of HA.....	85
Figure 4. 23: Molecular weight of bPEI-HA copolymer	86
Figure 4. 24: Molecular weight of Lf.....	86
Figure 4. 25: Molecular weight of bPEI-Lf conjugate.....	87
Figure 4. 26: Molecular weight of Chi.....	87
Figure 4. 27: Molecular weight of bPEI-Chi copolymer	88
Figure 4. 28: Molecular weight of Biodegradable bPEI	88
Figure 4. 29: Molecular weight of Biodegradable bPEI-Chi copolymer.....	89
Figure 5. 1: Agarose gel electrophoresis of bPEI-HA copolymer	102
Figure 5. 2: Agarose gel electrophoresis of bPEI-Lf conjugate.....	102
Figure 5. 3: Agarose gel electrophoresis of bPEI-Chi copolymer	103
Figure 5. 4: Agarose gel electrophoresis of biodegradable bPEI-Chi copolymer	103
Figure 5. 5: Particle size distribution of bPEI-Lf polyplexes	105
Figure 5. 6: Particle size distribution of bPEI-HA polyplexes	105
Figure 5. 7: Particle size distribution of bPEI-Chi polyplexes	106
Figure 5. 8: Particle size distribution of biodegradable bPEI-Chi polyplexes.....	106
Figure 5. 9: Particle size distribution of placebo liposomes	107
Figure 5. 10: Particle size distribution of lipopolyplexes	107
Figure 5. 11: Zeta potential of bPEI-HA copolymer	108
Figure 5. 12: Zeta potential of bPEI-HA polyplex	108
Figure 5. 13: Zeta potential of bPEI-Lf conjugate.....	109
Figure 5. 14: Zeta potential of bPEI-Lf polyplex	109
Figure 5. 15: Zeta potential of bPEI-Chi copolymer	110
Figure 5. 16: Zeta potential of bPEI-Chi polyplex	110
Figure 5. 17: Zeta potential of biodegradable bPEI-Chi copolymer.....	111
Figure 5. 18: Zeta potential of biodegradable bPEI-Chi polyplex.....	111
Figure 5. 19: Zeta potential of lipopolyplex	112

Figure 5. 20: Zeta potential of placebo liposomes	112
Figure 5. 21: Heparin competition assay of bPEI-HA polyplex	114
Figure 5. 22: Heparin competition assay of bPEI-Lf polyplex	114
Figure 5. 23: Heparin competition assay of bPEI-Chi polyplex	115
Figure 5. 24: Heparin competition assay of biodegradable bPEI-Chi polyplex	115
Figure 5. 25: Heparin competition assay of lipopolyplex	116
Figure 5. 26: Stability study of formed colloidal nanoplexes	117
Figure 5. 27: Ex-vivo nasal permeation study of bPEI-HA polyplex	117
Figure 5. 28: Ex-vivo nasal permeation study of bPEI-Lf polyplex	118
Figure 5. 29: Ex-vivo nasal permeation study of bPEI-Chi polyplex	118
Figure 5. 30: Ex-vivo nasal permeation study of bPEI-Chi polyplex	119
Figure 5. 31: Ex-vivo nasal permeation study of bPEI-Chi polyplex	119
Figure 6. 1: Representation of cell counting areas using hemocytometer	126
Figure 6. 2: Principle of MTT assay	127
Figure 6. 3: % cell viability of synthesized copolymers and conjugates	138
Figure 6. 4: Cell uptake study by confocal microscopy for polyplex and lipopolyplex	140
Figure 6. 5: Comparison of quantitative cell uptake of naked siRNA, PEI (0.8 kDa), biodegradable bPEI-Chi polyplex and lipopolyplex. (A) represents dot plots showing gated population of respective sample while (B) represents 2D histogram of population depicting Cyanine 5 positive and Cyanine 5 negative cells.....	141
Figure 6. 6: RT-PCR analysis of polyplex and lipopolyplex.....	142
Figure 7. 1: Graphical representation of % pump delivery of nasal spray pump	161
Figure 7. 2: Graphical representation of effect of resting time on % pump delivery from nasal spray pump.....	162
Figure 7. 3: Spray pattern for nasal spray at 3 cm	163
Figure 7. 4: Spray pattern for nasal spray at 6 cm	163
Figure 7. 5: Plume geometry of nasal spray at (A) 3 cm (B) 6 cm	164
Figure 7. 6: Droplet size distribution of nasal spray at spraying angle 30°	165
Figure 7. 7: Droplet size distribution of nasal spray at spraying angle 60°	166
Figure 7. 8: Droplet size distribution of nasal spray at spraying angle 90°	166
Figure 7. 9: Droplet size distribution of nasal spray at actuation force 35 N	167
Figure 7. 10: Droplet size distribution of nasal spray at actuation force 45 N	167
Figure 7. 11: Droplet size distribution of nasal spray at actuation distance 3 cm	168

Figure 7. 12: Droplet size distribution of nasal spray at actuation distance 6 cm	169
Figure 7. 13: Droplet size distribution of nasal spray at hold time 1 s	170
Figure 7. 14: Droplet size distribution of nasal spray at hold time 2 s	170
Figure 7. 15: Droplet size distribution of nasal spray at hold time 3 s	170
Figure 7. 16: Optimized droplet size distribution of nasal spray	171
Figure 7. 17: Influence of time on weight of nasal spray pump	172
Figure 7. 18: Droplet size distribution of nasal spray as tail-off characteristics.....	173
Figure 7. 19: Spray pattern for nasal spray as tail-off characteristic	174
Figure 7. 20: TAMC determination by spread plate technique on TSA plates.....	175
Figure 7. 21: TYMC determination by spread plate technique on SDA plates	175
Figure 8. 1: Representation of gel stack for transfer of bands on membrane	183
Figure 8. 2: Nasal ciliotoxicity study showing (A) PBS pH 7.4 (B) Isopropyl alcohol (C) Polyplex and (D) Lipopolyplex treated rat nasal mucosa.....	186
Figure 8. 3: Graphical representation of % brain distribution of different formulations	187
Figure 8. 4: NRG1 expression measured by western blot. Here (A) represent NRG1 expression while (B) represent expression of housekeeping β -actin gene.	188
Figure 8. 5: Graphical representation of % NRG1 expression using western blot	189
Figure 8. 6: Gene expression and knockdown efficiency of NRG1 siRNA estimated by RT-PCR.....	189
Figure 9. 1: % recovery and particle size of polyplex and lipopolyplex at various time points.....	195
Figure 9. 2: Plume geometry of nasal spray after 3 months at (A) 3 cm and (B) 6 cm	196
Figure 9. 3: Droplet size distribution of nasal spray at stability time points	196